 | |
- close
- close
|
MedPage Today
Nov 6
Comment
BOSTON (MedPage Today) -- Vitamin E and, potentially, pioglitazone (Actos) may become the first effective treatments for nonalcoholic steatohepatitis (NASH), a researcher said here.
PR Newswire
Nov 3
Comment
DEERFIELD, Ill., Nov. 3 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc., today announced the incorporation of Takeda Pharmaceuticals Mexico, S.A. de C.V. This expansion strengthens the company's North American presence, bolstering existing
Japan Today
Nov 3
Comment
Amylin Pharmaceuticals Inc says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co on potential weight-loss treatments.
Company…
Market Intelligence Center
Nov 2
Comment
Amylin Pharmaceuticals (AMLN) leads the list of top gainers so far today and is now at $12.14, up $1.10 (9.96%) on volume of 12,236,203 shares traded. Over the last 52 weeks the stock has ranged from a low of $5.50 to a high of $15.69. The stock...
FierceBiotech
Nov 2
Comment
There's a new entry in the closely-watched race to win approval for a blockbuster new weight loss drug. Amylin Pharmaceuticals announced this morning that it struck a billion-dollar development deal with Takeda for new obesity therapies that may...
StreetInsider.com
Nov 2
Comment
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Amylin+%28AMLN%29+and+Takeda+Enter+Development+Agreement+for+Obesity+Treatments/5062755.html for the full story.
Bloomberg
Nov 2
Comment
(Update1) Takeda Pharmaceutical Co., maker of
the world’s best-selling diabetes drug, agreed to pay as much as
$1 billion to Amylin Pharmaceuticals Inc. to co-develop obesity
treatments as it seeks to bolster declining sales.
PR Newswire
Nov 1
Comment
SAN DIEGO and OSAKA, Japan, Nov. 1, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license,
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
TKPHF AT A GLANCE
References
| ||||||
|
|
